The Topical Drugs Market size was valued at USD 195.77 billion in 2024 and is expected to reach USD 311.88 billion by 2032, growing at a CAGR of 6.02% over the forecast period of 2025-2032.
To Get more information on Topical Drugs Market - Request Free Sample Report
The rising prevalence of chronic diseases and skin ailments, as well as developments in drug delivery technologies, are driving the strong expansion of the topical drugs market.
For instance, the World Health Organization estimates that diabetes and skin conditions are major causes of 74% of global deaths attributed to chronic diseases.
Reflecting great regulatory backing, the U.S. Food and Drug Administration (FDA) keeps approving creative topical formulations. Rising with a CAGR of 5.96% during the forecast period, the U.S. topical drugs market was valued at USD 62.26 billion in 2024 and is expected to reach USD 98.71 billion by 2032, thereby accounted for a significant share of the global topical drugs market. North America leads in market share because of its high concentration of topical drug companies, modern healthcare infrastructure, and large R&D expenditure. Government figures show a rising desire for non-invasive treatments; topical drug delivery technologies are becoming more and more favored for their focused action and low systemic adverse effects. These elements are guiding the present topical drugs market trends and driving the market growth.
Convenience and efficacy of topical therapies are being enhanced by developments in medication delivery, including nanotechnology and transdermal patches. These developments improve skin absorption and enable regulated release, hence increasing patient compliance. Because they are non-invasive, almost 60% of North American patients choose topical treatments. China and India also show similar patterns, whereby tailored topical medications are becoming more easily available due to advancements in healthcare.
Market Dynamics
Drivers
Rising Global Prevalence of Skin Disorders and Chronic Diseases Is Hastening the Expansion of the Topical Drug Market
The need for topical medications is being driven by the explosion in skin conditions, including psoriasis, eczema, and atopic dermatitis, as well as by the worldwide increase in chronic diseases such as diabetes.
The National Center for Biotechnology Information (NCBI) reports that psoriasis affects almost 1.92% of Europeans and 1.5% of North Americans, so stressing a sizable patient pool needing continuous topical treatments.
With almost 75% of those affected living in low-and middle-income nations, the International Diabetes Federation (IDF) estimates global diabetes cases to rise from 643 million in 2030 to 783 million by 2045. This epidemiological trend directly fuels the expansion of the market since topical drug delivery systems are employed more and more to treat diabetic foot ulcers and neuropathic pain, therefore avoiding hepatic first-pass metabolism and enhancing patient outcomes.
The topical pharmaceuticals market is being revolutionized by fast developments in drug delivery technologies, including nanostructured lipid carriers, microemulsions, and transdermal patches. Predicting formulation behaviour, optimizing nanocarrier design, and developing customized topical treatments depending on patient-specific data, including skin type and medical history, depends on artificial intelligence (AI), which is today playing a vital role.
Topical Drug Adoption is Significantly Hampered by Adverse Skin Reactions and Patient Sensitivities
Widespread use of topical drugs is often limited by the risk of skin irritation, allergic reactions, and sensitization, which can cause mild pain to severe responses needing medical intervention, often limiting the widespread use of topical medications. The variation in personal skin types and sensitivity makes it more difficult to create generally safe formulas, so the manufacturers' burden of doing comprehensive safety and compatibility testing is raised. The regulatory environment reflects this difficulty as authorities, including the European Medicines Agency (EMA), have developed new rules on the quality and equivalency of locally applied, locally acting cutaneous products, effective from April 2025. These rules stress strict in vitro release and permeation testing to guarantee product safety and efficacy, therefore adding to the difficulty and expense of introducing novel topical medications to the market. Such negative consequences and regulatory scrutiny might cause delays in product introductions and restrict patient adoption, restraining overall market growth.
By Route Of Administration
With a 55% share, the dermal medication delivery retained the highest topical medicines market share in 2024. The great frequency of skin illnesses and the efficiency of dermal formulations in offering localized therapy help to explain this predominance. The American Academy of Dermatology estimates that skin problems impact over 85 million Americans yearly, which fuels demand for improved dermal treatments. The U.S. FDA has approved several novel dermal products, therefore demonstrating regulatory support for innovation in recent years. One prominent topical drugs market trend is artificial intelligence-driven formulation development; AI tools now forecast ideal nanocarrier compositions for improved drug penetration and stability.
For instance, using microencapsulation technology, Sol-Gel Technologies and Galderma introduced Epsolay (benzoyl peroxide cream), for which FDA clearance was granted in April 2022.
The ophthalmic drug delivery segment is predicted to grow at high pace, driven by the rising frequency of eye diseases. The CDC notes the need for efficient ophthalmic therapies since 12 million Americans forty years of aged and above suffer vision problems. Improving drug retention and patient outcomes, recent advancements include the introduction of nanotechnology-based delivery methods and sustained-release ophthalmic formulations.
For instance, reflecting the area's dedication to creative therapies, Germany became the first nation in October 2024 to introduce LEO Pharma's Anzupgo (delgocitinib) cream for severe hand eczema.
By Type
With a 60% revenue share in 2024, the semi-solid formulations segment dominated the topical drug market. These formulations are preferred for their simplicity of application, adaptability, and capacity to deliver continuous targeted treatment. Reflecting strong regulatory support, the U.S. FDA and EMA have fast-tracked semi-solid goods. Cost savings and rising demand for dermatology goods are driving the Asia Pacific region, especially India and China, as a manufacturing hub due to cost efficiencies.
For example, LGM Pharma spent more than USD 6 million in March 2025 to expand its Texas facility, so increasing capacity for semi-solid and liquid medication manufacture obvious indication of Topical Drugs Market Growth.
Particularly in ophthalmic and wound care uses, liquid formulations should show a notable increase. These formulations are appropriate for elderly and young individuals and show quick absorption. Supported by legislative changes and more healthcare expenditure, the Asia Pacific region is seeing a surge in liquid formulation manufacturing. Upperton Pharma Solutions completed a new sterile manufacturing plant in the UK in January 2025 to improve the capacity of the area to provide liquid topical treatments.
By End Use
Hospitals and clinics held the largest topical drugs market share 39%, in 2024. This is a result of the great number of individuals needing specific treatment for ocular and dermatological diseases. The global hospital services market was valued at USD 4.38 trillion in 2023 with North America owning a 38.56% of global share. Although public and community hospitals predominate, their emphasis on advanced and specialized treatment is helping private hospitals to gaining share.
Driven by growing burn injury cases and more investment in specialist care, burn centers are expected to see significant growth of topical drugs market. Government programs aimed at enhancing emergency care help to explain the rising number of specialists burn units. Reflecting continuing infrastructure investment, Tampa General Hospital opened a new regional burn center in March 2023.
In 2024, North America accounted for approximately 39% of the global topical drug market. While a supportive reimbursement system promotes the acceptance of premium and patented topical medicines, strict regulatory criteria guarantee product safety and efficacy. Remarkably strong over-the-counter (OTC) sales reflect a health-conscious populace and great consumer awareness. Increased R&D expenditure and the acceptance of new technologies such as nanotechnology and microencapsulation for better drug delivery are driving the North America's contract development and manufacturing organization (CDMO) market is thriving. These factors collectively drive sustained topical drugs market growth and reinforce North America’s leadership in the global landscape.
By 2032, the U.S. topical drugs market is expected to reach USD 98.71 billion. Major topical medicine companies, strong research and development infrastructure, and a favourable regulatory environment headed by the U.S. Food and Drug Administration (FDA) are driving this rise. The region is a hub for innovation, with so many startups and established companies creating innovative delivery methods, including micro-needles, patches, and gels to improve drug absorption and efficacy.
The Asia Pacific region is expected to be the fastest-growing region with a CAGR of 6.53% over the forecast period in the global topical drug market. Cost-effective production, a developing pharmaceutical sector, and large patient pools in nations including China, India, and Indonesia help to explain this expansion. The growing middle class in the area, rising disposable incomes, and rising healthcare costs have driven demand for both generic and creative topical medications. Driven by increasing urbanization, legislative changes, and a sizable population base, China especially stands out as the fastest-growing nation in the sector. Given that most multinational medicine companies run production facilities in India, the country's global supply of reasonably priced topical generics is especially important.
Europe holds a prominent position in the topical drugs market. Strong regulations, strict standards of quality for manufacturing, and an emphasis on invention define the market. Leading pharmaceutical companies and CDMOs guarantee product safety and efficacy by using modern technology and upholding strict compliance with EU rules. With the NCBI noting a psoriasis incidence of 1.92% in Europe, skin illnesses, including psoriasis and eczema, continue to be rather common. This is in line with a consistent flow of new product introductions and strategic alliances since Novartis AG's acquisition of Kedalion Therapeutics for ocular medication delivery technology keeps driving market expansion.
Supported by increasing government investment in healthcare facilities and growing pharmaceutical spending, the LAMEA area is seeing a consistent topical drug market expansion. Leading market in Latin America, Brazil gains from a rising middle class and increased access to healthcare facilities. Saudi Arabia and other Middle Eastern nations are making major progress in pharmaceutical manufacture and healthcare modernization, drawing both local and foreign topical medicine companies. LAMEA is likely to become more and more significant in the worldwide topical medications market as these nations keep spending on healthcare infrastructure and implementing global best practices.
Get Customized Report as per Your Business Requirement - Enquiry Now
The key topical drugs companies are Bayer AG, MedPharm Ltd., Encore Dermatology Inc., GSK plc, Johnson & Johnson Services, Inc., Cipla, Novartis AG, Bausch Health Companies Inc., Crescita Therapeutics Inc., Merck KGaA, GLENMARK PHARMACEUTICALS LTD., Hisamitsu Pharmaceuticals Co., Inc., Taro Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Sanofi, and others.
Targeting the IL-23 protein, Astellas Pharma launched a novel prescription topical foam called Skyrizi in April 2023 for treating plaque psoriasis in adults.
Acting by blocking the JAK1 protein, Novartis introduced Xeljanz Cream, a topical therapy for adult plaque psoriasis, in March 2023.
Supporting pharmaceutical formulation innovation in Asia Pacific, Clariant debuted eight new excipients at CPHI India in November 2024.
| Report Attributes | Details |
| Market Size in 2024 | USD 195.77 Billion |
| Market Size by 2032 | USD 311.88 Billion |
| CAGR | CAGR of 6.02% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Route of Administration (Dermal Drug Delivery, Vaginal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery) • By Type (Semi-solid Formulations, Solid Formulations, Liquid Formulations, Transdermal Products) • By End Use (Home Care Settings, Burn Centers, Hospitals & Clinics, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bayer AG, MedPharm Ltd., Encore Dermatology Inc., GSK plc, Johnson & Johnson Services, Inc., Cipla, Novartis AG, Bausch Health Companies Inc., Crescita Therapeutics Inc., Merck KGaA, GLENMARK PHARMACEUTICALS LTD., Hisamitsu Pharmaceuticals Co., Inc., Taro Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Sanofi, and others |
Ans. The projected market size for the Topical Drugs Market is USD 311.88 billion by 2032.
Ans: The North America region dominated the Topical Drugs Market in 2024.
Ans. The CAGR of the Topical Drugs Market is 6.02% during the forecast period of 2025-2032.
Ans: Topical Drug Adoption is Significantly Hampered by Adverse Skin Reactions and Patient Sensitivities
Ans: The Hospitals & Clinics segment dominated the Topical Drugs Market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Topical Drug Volume (Production and Usage)
5.2 Healthcare Spending Related to Topical Drugs (2023)
5.3 Market Segmentation Trends by Drug Formulation and Delivery Type
5.4 Regulatory and Safety Compliance Trends (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Topical Drugs Market Segmentation By Route of Administration
7.1 Chapter Overview
7.2 Dermal Drug Delivery
7.2.1 Dermal Drug Delivery Market Trends Analysis (2021-2032)
7.2.2 Dermal Drug Delivery Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Vaginal Drug Delivery
7.3.1 Vaginal Drug Delivery Market Trends Analysis (2021-2032)
7.3.2 Vaginal Drug Delivery Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Nasal Drug Delivery
7.4.1 Nasal Drug Delivery Market Trends Analysis (2021-2032)
7.4.2 Nasal Drug Delivery Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Ophthalmic Drug Delivery
7.5.1 Ophthalmic Drug Delivery Market Trends Analysis (2021-2032)
7.5.2 Ophthalmic Drug Delivery Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Rectal Drug Delivery
7.6.1 Rectal Drug Delivery Market Trends Analysis (2021-2032)
7.6.2 Rectal Drug Delivery Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Topical Drugs Market Segmentation By Type
8.1 Chapter Overview
8.2 Semi-solid Formulations
8.2.1 Semi-solid Formulations Market Trend Analysis (2021-2032)
8.2.2 Semi-solid Formulations Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 Creams
8.2.3.1 Creams Market Trends Analysis (2021-2032)
8.2.3.2 Creams Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 Gel
8.2.4.1 Gel Market Trends Analysis (2021-2032)
8.2.4.2 Gel Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.5 Ointments
8.2.5.1 Ointments Market Trends Analysis (2021-2032)
8.2.5.2 Ointments Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.6 Lotions
8.2.6.1 Lotions Market Trends Analysis (2021-2032)
8.2.6.2 Lotions Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.7 Pastes
8.2.7.1 Pastes Market Trends Analysis (2021-2032)
8.2.7.2 Pastes Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Solid Formulations
8.3.1 Solid Formulations Market Trends Analysis (2021-2032)
8.3.2 Solid Formulations Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.3 Powders
8.3.3.1 Powders Market Trends Analysis (2021-2032)
8.3.3.2 Powders Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.4 Suppositories
8.3.4.1 Suppositories Market Trends Analysis (2021-2032)
8.3.4.2 Suppositories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Liquid Formulations
8.4.1 Liquid Formulations Market Trends Analysis (2021-2032)
8.4.2 Liquid Formulations Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4.3 Suspensions
8.4.3.1 Suspensions Market Trends Analysis (2021-2032)
8.4.3.2 Suspensions Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4.4 Solutions
8.4.4.1 Solutions Market Trends Analysis (2021-2032)
8.4.4.2 Solutions Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Transdermal Products
8.5.1 Transdermal Products Market Trends Analysis (2021-2032)
8.5.2 Transdermal Products Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5.3 Transdermal Semi-Solids
8.5.3.1 Transdermal Semi-Solids Market Trends Analysis (2021-2032)
8.5.3.2 Transdermal Semi-Solids Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5.4 Transdermal Patches
8.5.4.1 Transdermal Patches Market Trends Analysis (2021-2032)
8.5.4.2 Transdermal Patches Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Topical Drugs Market Segmentation By End Use
9.1 Chapter Overview
9.2 Home Care Settings
9.2.1 Home Care Settings Market Trends Analysis (2021-2032)
9.2.2 Home Care Settings Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Burn Centers
9.3.1 Burn Centers Market Trends Analysis (2021-2032)
9.3.2 Burn Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Hospitals & Clinics
9.4.1 Hospitals & Clinics Market Trends Analysis (2021-2032)
9.4.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2021-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Topical Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.4 North America Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.2.5 North America Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.6.2 USA Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.2.6.3 USA Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.7.2 Canada Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.2.7.3 Canada Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.8.2 Mexico Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.2.8.3 Mexico Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Topical Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.4 Europe Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.5 Europe Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.6.2 Germany Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.6.3 Germany Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.7.2 France Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.7.3 France Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.8.2 UK Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.8.3 UK Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.9.2 Italy Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.9.3 Italy Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.10.2 Spain Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.10.3 Spain Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.11.2 Poland Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.11.3 Poland Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.12.2 Turkey Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.12.3 Turkey Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Topical Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.4 Asia Pacific Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.5 Asia Pacific Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.6.2 China Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.6.3 China Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.7.2 India Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.7.3 India Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.8.2 Japan Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.8.3 Japan Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.9.2 South Korea Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.9.3 South Korea Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.10.2 Singapore Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.10.3 Singapore Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.11.2 Australia Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.11.3 Australia Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Topical Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.6.2 UAE Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.5.6.3 UAE Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.8.2 Qatar Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.5.8.3 Qatar Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.9.2 South Africa Topical Drugs Market Estimates and Forecasts By Type (2021-2032) (USD Billion)
10.5.9.3 South Africa Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Topical Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.4 Latin America Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.6.5 Latin America Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.6.2 Brazil Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.6.6.3 Brazil Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.7.2 Argentina Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.6.7.3 Argentina Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Topical Drugs Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Topical Drugs Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Topical Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
11. Company Profiles
11.1 Bayer AG
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 MedPharm Ltd.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Encore Dermatology Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 GSK plc
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Johnson & Johnson Services, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Cipla
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Bausch Health Companies Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Crescita Therapeutics Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Merck KGaA
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Route of Administration
Dermal Drug Delivery
Vaginal Drug Delivery
Nasal Drug Delivery
Ophthalmic Drug Delivery
Rectal Drug Delivery
By Type
Semi-solid Formulations
Creams
Gel
Ointments
Lotions
Pastes
Solid Formulations
Powders
Suppositories
Liquid Formulations
Suspensions
Solutions
Transdermal Products
Transdermal Semi-Solids
Transdermal Patches
By End Use
Home Care Settings
Burn Centers
Hospitals & Clinics
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
